Unveiling the therapeutical potential of Tupistra clarkei in diabetic neuropathic pain on Wistar albino rats: A Himalayan Gem

Background and aims

Diabetic neuropathy is a long-existing painful neuronal error associated with high sugar levels, hyperalgesia, and slowed motor nerve conduction. Therefore, the study aims to investigate the efficacy of the methanolic extract of Tupistra clarkei (METC) against diabetes-inducing neuropathy in Wistar albino rats. The potential of these findings to inspire hope for improved treatment strategies for diabetic neuropathy is significant and inspiring, offering a promising outlook for the future.

Method and results

Phytochemical and acute toxicity screening were carried out using METC. Then, Streptozotocin induces hyperglycaemia followed by neuropathy was carried out in five groups of animals such as the normal control (NC), Diabetic control (DC), The standard control (Std), The low-dose (100 mg/kg), the high-dose group (200 mg/kg). After regular observation of motor nerve conduction, neuropathic assays, and inflammatory mediators for the 8th week, animals were sacrificed using ketamine hydrochloride. The sciatic nerve was isolated, then subjected to histopathological analysis using an Olympus binocular microscope at 45X, and subjected to antioxidant study. METC reported the presence of alkaloids, carbohydrates, flavonoids, saponins, and steroids. The results of the LC-MS analysis of the METC samples detected at peak m/z 371.1100 could be responsible for the antidiabetic property of Tupistra clarkei. In addition, the results indicate significant restoration of oxidative stress, nerve conduction, inflammatory pain, elevated blood glucose levels related to hyperalgesia, motor nerve conduction, and reversible curing of cellular injury.

Conclusion

METC controls and prevents diabetes-induced neuropathic pain and related complications such as nerve conduction, raised temperature threshold, and extended latency in hyperalgesia.